Prelude therapeutics announces publication of abstracts for presentation at the 36th eortc-nci-aacr symposium

Prt3789, a novel, highly-selective smarca2 degrader in patients with advanced solid tumors with a smarca4 mutation plenary session presentation: october 24, 2024, 10:00 am cest (4:00 am est) prt3789, a novel, highly-selective smarca2 degrader in patients with advanced solid tumors with a smarca4 mutation plenary session presentation: october 24, 2024, 10:00 am cest (4:00 am est)
NCI Ratings Summary
NCI Quant Ranking